Immunotherapy [including antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand-1 (PD-L1)] is the most important development in cancer therapy of the past 10 years. This evidence concerns the gene PDCD1 and cancer.